{"entity":{"type":"insider","cik":"0001810417","url":"/insider/0001810417","json_url":"/insider/0001810417.json","name":"Sullivan Christopher Ryan","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":19,"n_filings":9,"first":"2020-06-11","last":"2026-08-19","span_basis":"filed_date"},"name_variants":[{"name":"Sullivan Christopher Ryan","source":"filing","n_filings":9,"first_seen":"2020-06-11","last_seen":"2026-08-19"}],"transactions":[{"id":9298738,"accession":"0001810417-26-000019","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001810417-26-000019","line_url":"/filing/0001810417-26-000019#line-3","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":"0001810417","owner_name":"Sullivan Christopher Ryan","owner_url":"/insider/0001810417","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":31031.0,"shares_display":"31,031","price_per_share":20.0549,"price_display":"20.05","price_state":"stated","total_value":622323.6019,"total_display":"622,323.60","shares_owned_after":39900.0,"shares_owned_after_display":"39,900","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-08-18","filed_date":"2026-08-19","scope":"insider"},{"id":9298737,"accession":"0001810417-26-000019","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001810417-26-000019","line_url":"/filing/0001810417-26-000019#line-2","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":"0001810417","owner_name":"Sullivan Christopher Ryan","owner_url":"/insider/0001810417","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3749.0,"shares_display":"3,749","price_per_share":19.9419,"price_display":"19.94","price_state":"stated","total_value":74762.1831,"total_display":"74,762.18","shares_owned_after":39900.0,"shares_owned_after_display":"39,900","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-08-17","filed_date":"2026-08-19","scope":"insider"},{"id":9298736,"accession":"0001810417-26-000019","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001810417-26-000019","line_url":"/filing/0001810417-26-000019#line-1","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":"0001810417","owner_name":"Sullivan Christopher Ryan","owner_url":"/insider/0001810417","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":37945.0,"shares_display":"37,945","price_per_share":19.8533,"price_display":"19.85","price_state":"stated","total_value":753333.4685,"total_display":"753,333.47","shares_owned_after":43649.0,"shares_owned_after_display":"43,649","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-08-17","filed_date":"2026-08-19","scope":"insider"},{"id":6225377,"accession":"0001810417-26-000012","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001810417-26-000012","line_url":"/filing/0001810417-26-000012#line-2","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":"0001810417","owner_name":"Sullivan Christopher Ryan","owner_url":"/insider/0001810417","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":18606.0,"shares_display":"18,606","price_per_share":24.1222,"price_display":"24.12","price_state":"stated","total_value":448817.6532,"total_display":"448,817.65","shares_owned_after":423.0,"shares_owned_after_display":"423","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-05-07","filed_date":"2026-05-11","scope":"insider"},{"id":6141578,"accession":"0001810417-26-000010","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001810417-26-000010","line_url":"/filing/0001810417-26-000010#line-6","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":"0001810417","owner_name":"Sullivan Christopher Ryan","owner_url":"/insider/0001810417","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":13834.0,"shares_display":"13,834","price_per_share":18.5525,"price_display":"18.55","price_state":"stated","total_value":256655.285,"total_display":"256,655.28","shares_owned_after":33589.0,"shares_owned_after_display":"33,589","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-05-06","filed_date":"2026-05-07","scope":"insider"},{"id":6141577,"accession":"0001810417-26-000010","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001810417-26-000010","line_url":"/filing/0001810417-26-000010#line-5","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":"0001810417","owner_name":"Sullivan Christopher Ryan","owner_url":"/insider/0001810417","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12347.0,"shares_display":"12,347","price_per_share":19.2835,"price_display":"19.28","price_state":"stated","total_value":238093.3745,"total_display":"238,093.37","shares_owned_after":21242.0,"shares_owned_after_display":"21,242","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-05-06","filed_date":"2026-05-07","scope":"insider"},{"id":6141575,"accession":"0001810417-26-000010","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001810417-26-000010","line_url":"/filing/0001810417-26-000010#line-4","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":"0001810417","owner_name":"Sullivan Christopher Ryan","owner_url":"/insider/0001810417","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":9219.0,"shares_display":"9,219","price_per_share":21.3698,"price_display":"21.37","price_state":"stated","total_value":197008.1862,"total_display":"197,008.19","shares_owned_after":9323.0,"shares_owned_after_display":"9,323","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-05-06","filed_date":"2026-05-07","scope":"insider"},{"id":6141574,"accession":"0001810417-26-000010","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001810417-26-000010","line_url":"/filing/0001810417-26-000010#line-3","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":"0001810417","owner_name":"Sullivan Christopher Ryan","owner_url":"/insider/0001810417","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8900.0,"shares_display":"8,900","price_per_share":22.5745,"price_display":"22.57","price_state":"stated","total_value":200913.05,"total_display":"200,913.05","shares_owned_after":423.0,"shares_owned_after_display":"423","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-05-06","filed_date":"2026-05-07","scope":"insider"},{"id":6141573,"accession":"0001810417-26-000010","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001810417-26-000010","line_url":"/filing/0001810417-26-000010#line-2","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":"0001810417","owner_name":"Sullivan Christopher Ryan","owner_url":"/insider/0001810417","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2700.0,"shares_display":"2,700","price_per_share":20.76,"price_display":"20.76","price_state":"stated","total_value":56052.0,"total_display":"56,052.00","shares_owned_after":18542.0,"shares_owned_after_display":"18,542","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-05-06","filed_date":"2026-05-07","scope":"insider"},{"id":5779333,"accession":"0001810417-26-000008","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001810417-26-000008","line_url":"/filing/0001810417-26-000008#line-2","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":"0001810417","owner_name":"Sullivan Christopher Ryan","owner_url":"/insider/0001810417","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8457.0,"shares_display":"8,457","price_per_share":13.2261,"price_display":"13.23","price_state":"stated","total_value":111853.1277,"total_display":"111,853.13","shares_owned_after":423.0,"shares_owned_after_display":"423","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-04-30","filed_date":"2026-05-01","scope":"insider"},{"id":5779332,"accession":"0001810417-26-000008","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001810417-26-000008","line_url":"/filing/0001810417-26-000008#line-1","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":"0001810417","owner_name":"Sullivan Christopher Ryan","owner_url":"/insider/0001810417","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8458.0,"shares_display":"8,458","price_per_share":13.0925,"price_display":"13.09","price_state":"stated","total_value":110736.365,"total_display":"110,736.36","shares_owned_after":8880.0,"shares_owned_after_display":"8,880","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-04-29","filed_date":"2026-05-01","scope":"insider"},{"id":5789296,"accession":"0001810417-26-000006","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001810417-26-000006","line_url":"/filing/0001810417-26-000006#line-4","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":"0001810417","owner_name":"Sullivan Christopher Ryan","owner_url":"/insider/0001810417","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6200.0,"shares_display":"6,200","price_per_share":17.0247,"price_display":"17.02","price_state":"stated","total_value":105553.14,"total_display":"105,553.14","shares_owned_after":19118.0,"shares_owned_after_display":"19,118","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-04-02","filed_date":"2026-04-03","scope":"insider"},{"id":5789295,"accession":"0001810417-26-000006","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001810417-26-000006","line_url":"/filing/0001810417-26-000006#line-3","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":"0001810417","owner_name":"Sullivan Christopher Ryan","owner_url":"/insider/0001810417","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1780.0,"shares_display":"1,780","price_per_share":17.5674,"price_display":"17.57","price_state":"stated","total_value":31269.972,"total_display":"31,269.97","shares_owned_after":17338.0,"shares_owned_after_display":"17,338","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-04-02","filed_date":"2026-04-03","scope":"insider"},{"id":5789293,"accession":"0001810417-26-000006","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001810417-26-000006","line_url":"/filing/0001810417-26-000006#line-2","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":"0001810417","owner_name":"Sullivan Christopher Ryan","owner_url":"/insider/0001810417","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7479.0,"shares_display":"7,479","price_per_share":16.8259,"price_display":"16.83","price_state":"stated","total_value":125840.9061,"total_display":"125,840.91","shares_owned_after":25318.0,"shares_owned_after_display":"25,318","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-04-01","filed_date":"2026-04-03","scope":"insider"},{"id":5789291,"accession":"0001810417-26-000006","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001810417-26-000006","line_url":"/filing/0001810417-26-000006#line-1","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":"0001810417","owner_name":"Sullivan Christopher Ryan","owner_url":"/insider/0001810417","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":500.0,"shares_display":"500","price_per_share":15.858,"price_display":"15.86","price_state":"stated","total_value":7929.0,"total_display":"7,929.00","shares_owned_after":32797.0,"shares_owned_after_display":"32,797","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-04-01","filed_date":"2026-04-03","scope":"insider"},{"id":8639587,"accession":"0001628280-23-021962","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001628280-23-021962","line_url":"/filing/0001628280-23-021962#line-1","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":"0001810417","owner_name":"Sullivan Christopher Ryan","owner_url":"/insider/0001810417","role":"Officer (Chief Financial Officer)","officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":511.0,"shares_display":"511","price_per_share":3.42,"price_display":"3.42","price_state":"stated","total_value":1747.62,"total_display":"1,747.62","shares_owned_after":1262.0,"shares_owned_after_display":"1,262","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-06-09","filed_date":"2023-06-13","scope":"insider"},{"id":5421959,"accession":"0001879785-21-000039","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001879785-21-000039","line_url":"/filing/0001879785-21-000039#line-1","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Avalo Therapeutics, Inc.","issuer_ticker":"AVTX","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":"0001810417","owner_name":"Sullivan Christopher Ryan","owner_url":"/insider/0001810417","role":"Officer (Chief Accounting Officer)","officer_title":"Chief Accounting Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":955.0,"shares_display":"955","price_per_share":1.57,"price_display":"1.57","price_state":"stated","total_value":1499.35,"total_display":"1,499.35","shares_owned_after":9004.0,"shares_owned_after_display":"9,004","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-12-10","filed_date":"2021-12-14","scope":"insider"},{"id":2266336,"accession":"0001192482-20-000818","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001192482-20-000818","line_url":"/filing/0001192482-20-000818#line-1","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Cerecor Inc.","issuer_ticker":"CERC","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":"0001810417","owner_name":"Sullivan Christopher Ryan","owner_url":"/insider/0001810417","role":"Officer (Interim CFO)","officer_title":"Interim CFO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5095.0,"shares_display":"5,095","price_per_share":2.278,"price_display":"2.28","price_state":"stated","total_value":11606.41,"total_display":"11,606.41","shares_owned_after":8049.0,"shares_owned_after_display":"8,049","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-12-10","filed_date":"2020-12-14","scope":"insider"},{"id":2816908,"accession":"0001192482-20-000486","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001192482-20-000486","line_url":"/filing/0001192482-20-000486#line-1","is_derivative":false,"issuer_cik":"0001534120","issuer_name":"Cerecor Inc.","issuer_ticker":"CERC","issuer_name_source":null,"issuer_url":"/issuer/0001534120","owner_cik":"0001810417","owner_name":"Sullivan Christopher Ryan","owner_url":"/insider/0001810417","role":"Officer (Interim CFO)","officer_title":"Interim CFO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2954.0,"shares_display":"2,954","price_per_share":2.278,"price_display":"2.28","price_state":"stated","total_value":6729.212,"total_display":"6,729.21","shares_owned_after":2954.0,"shares_owned_after_display":"2,954","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-06-10","filed_date":"2020-06-11","scope":"insider"}],"next_cursor":null,"ledger_fault":false,"count":{"value":19,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":4,"open_market":true},{"code":"S","label":"Open-market sale","n":15,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":19},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001534120","name":"Avalo Therapeutics, Inc.","url":"/issuer/0001534120","role":"Officer (Chief Financial Officer)","n_filings":9,"first_seen":"2020-06-11","last_seen":"2026-08-19"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001810417","retrieved_at":"2026-08-21T05:27:58+00:00","coverage":{"filings":1505395,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-20","last_ingest":"2026-08-21T05:23:33.898496+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}